The average one-year price target for Editas Medicine (NasdaqGS:EDIT) has been revised to $4.95 / share. This is an increase of 22.78% from the prior estimate of $4.03 dated November 14, 2025. The ...

Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to ...

Target’s spring Circle Week is almost here – it begins this Sunday, July 6 and lasts through Saturday, July 12 for Target Circle members. The June 30 announcement confirmed you can expect seven days ...

Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective raised by Wells Fargo & Company from $3.00 to $4.00 in a research note issued to investors on Wednesday,Benzinga reports. They ...